Hepatocellular Carcinoma (HCC)


HCC is a major health problem worldwide and, although we have made progress in preventing it, treatment of HCC is just getting started. TARGET-HCC collects real world data on HCC treatment at academic sites, in clinical practice, through the US and in Europe. TARGET-HCC is an important tool for tracking our progress towards complete control of HCC. Adrian Di Bisceglie, MD

To date, significant research progress has been made in the field of Hepatocellular Carcinoma (HCC). However, the disease continues to be the most common type of primary liver cancer, further supporting the need for real-world data and insights to appropriately address gaps and advance the disease field.

TARGET-HCC is a 5-year longitudinal, observational study of the natural history and management of patients with HCC, within academic and community practices. The study was launched to collect real-world patient data to better understand the clinical characteristics, patterns, outcomes, and management of this disease in the real-world setting as well as assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

The HCC platform aggregates structured and unstructured data from medical records and patient-reported outcome measures and collects biospecimen samples. Partners can query the longitudinal dataset and analyses biospecimens linked to validated clinical data to support their drug development programs and RWE initiatives.

Study Goals:

  • Understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice

  • Evaluate the impact of HCC treatment interventions and concomitant medications on co-morbid conditions and liver function

  • Evaluate patient-reported outcomes measured during the natural course and management of HCC


September 2016


Enrollment Goal:

Up to 5,000

TARGET-HCC Steering Committee

Adrian Di Bisceglie, MD (Co-Chair)
Chief of Hepatology and University Liver Center Co-Director, St. Louis, MO

Anthony El-Khoueiry, MD (Co-Chair)
Associate Professor of Clinical Medicine, Los Angeles, CA

Roniel Cabrera, MD, MS (Protocol Author)
Director & Associate Professor of Medicine, Gainesville, FL

Michael W. Fried, MD (Scientific Advisor)  
Professor of Medicine and UNC Liver Center Director, Chapel Hill, NC

David Nelson, MD (Scientific Advisor)
Senior VP of Health Affairs and UF Health President, Gainesville, FL

Bruno Sangro, MD 
Director of the Liver Unit and Professor of Internal Medicine, Navarra, Spain

R. Kate (Katie) Kelley, MD 
Associate Professor of Clinical Medicine, San Francisco, CA

Massimo Colombo, MD 
Director of the Center for Translational Research in Liver Disease, Rozzano, Italy

Tim Meyer, MD 
Professor of Experimental Cancer Medicine, London, UK

Amit Singal, MD
Director of the Liver Tumor Program and Clinical Chief of Hepatology, Dallas, TX

Interested in launching a new disease registry?

Target RWE has developed a turnkey health evidence solution to rapidly activate disease agnostic registries to support partners.